Related Experiment Video

Updated: May 15, 2026

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

CCN6: a novel method of aTAKing cancer

Andrew Leask1

  • 1Departments of Dentistry and Physiology and Pharmacology, University of Western Ontario, Dental Sciences Building, London, ON, Canada, N6A 5C1, Andrew.leask@schulich.uwo.ca.

Journal of Cell Communication and Signaling
|January 8, 2013
PubMed

Insights

Targeting CCN6 (WISP3) may offer a novel therapeutic strategy for breast cancer. Downregulation of CCN6 promotes tumor survival by activating pathways like TAK1, suggesting CCN6 as a selective therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The CCN family of matricellular proteins plays a role in various cancers.
  • CCN6 (WISP3) is downregulated in aggressive breast cancers, contributing to tumor survival.
  • CCN6 downregulation promotes Akt phosphorylation and tumor progression.

Purpose of the Study:

  • To investigate the role of CCN6 in breast cancer.
  • To explore CCN6 as a potential therapeutic target for breast cancer.

Main Methods:

  • Analysis of CCN6 expression in breast cancer tissues.
  • Investigating the relationship between CCN6, BMP4, and phospho-p38 levels.
  • Examining the effects of CCN6 knockdown on signaling pathways.

Main Results:

  • CCN6 expression is inversely associated with BMP4 and phospho-p38 in 69% of invasive breast carcinomas.
  • CCN6 knockdown promotes BMP4-mediated activation of TAK1 and p38 kinases.
  • CCN6 downregulation appears to promote tumor survival via Akt phosphorylation.

Conclusions:

  • CCN6 may serve as a selective therapeutic target for breast cancer.
  • Targeting CCN6 offers a potential alternative to directly targeting TAK1.
  • Modulating CCN6 could represent a novel therapeutic strategy for breast cancer treatment.

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...